000			01602 a2200445 4500
005			20250514020202.0
264		0	_c20020418
008			200204s 0 0 eng d
022			_a0171-967X
024	7		_a10.1007/s00223-001-1060-8 _2doi
040			_aNLM _beng _cNLM
100	1		_aReid, D M
245	0	0	_aRisedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. _h[electronic resource]
260			_bCalcified tissue international _cOct 2001
300			_a242-7 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aBone Density _xdrug effects
650	0	4	_aBone and Bones _xdrug effects
650	0	4	_aCalcium Channel Blockers _xtherapeutic use
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDouble-Blind Method
650	0	4	_aEtidronic Acid _xanalogs & derivatives
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aOsteoporosis _xchemically induced
650	0	4	_aPrednisone _xadverse effects
650	0	4	_aRisedronic Acid
650	0	4	_aSpinal Fractures _xchemically induced
650	0	4	_aTreatment Outcome
700	1		_aAdami, S
700	1		_aDevogelaer, J P
700	1		_aChines, A A
773	0		_tCalcified tissue international _gvol. 69 _gno. 4 _gp. 242-7
856	4	0	_uhttps://doi.org/10.1007/s00223-001-1060-8 _zAvailable from publisher's website
999			_c11644207 _d11644207